Quick Takeaways: Why It Matters? Vivesto’s Paccal Vet program could expand treatment options in veterinary oncology, an area with significant unmet needs in canine and feline cancer care. Positive preliminary findings across two species support further clinical developmen...
Quick Takeaways: Why It Matters? BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level. Ins...
